Similarly, human epithelial growth factor receptor 2 (HER2) positivity, which is observed in approximately 30% of breast cancers, is an important marker for selecting targeted therapy with the monoclonal anti-HER2 antibody trastuzumab (HerceptinTM) [2-6]. Here, ERBB2 is linked to breast cancer.